YTTRIUM-90 ZEVALIN RADIOIMMUNOTHERAPY

DATE: 12/22/2005

PROCEDURE:  After obtaining informed patent consent, Y-90 Zevalin therapy was administered intravenously for antibody therapy treatment of B-cell lymphoma.

DOSE:  [...] mCi of Y-90 Zevalin.

CLINICAL HISTORY: The patient is a [...]-year-old [fe]male with past medical history significant for relapsing marginal zone B-cell lymphoma, who is referred for treatment with Yttrium-90 Zevalin.

CONCLUSIONS:

The administration of Y-90 Zevalin was performed intravenously on an outpatient basis.  The patient was given the usual precautions regarding radiation safety including avoiding close contact with pregnant women and young children for the next 48-72 hours.  The patient will be followed up by oncology.

Thank you for referring this patient to the UCLA Nuclear Medicine Clinic.

I, [...], M.D., Ph.D., have reviewed this Nuclear Medicine study personally, and am in full agreement with the findings of the report presented here.